

Please complete this enrollment form/profile sheet for each infusion center in your practice or group, and fax to 1-888-782-6157 or enroll online at ALSCareDirectory.com. Completing this enrollment form enrolls your practice or infusion service in the Mitsubishi Tanabe Pharma America, Inc. ALS Care Locator available on radicava.com. The ALS Care Locator website enables a user to locate an infusion site of care that has indicated it is capable of administering RADICAVA® (edaravone). Your site of care and profile information will be publicly available at radicava.com. If you have questions, please call Searchlight Support® at 1-844-772-4548.

The ALS Care Locator is an information resource only regarding available treatment providers. The providers listed in the directory are under no obligation to provide treatment.

Asterisk (*) indicates required field.

- *My facility can administer RADICAVA® I would like to be contacted to receive product access training
Infusion sites must be capable of providing infusion services for RADICAVA® to participate in the locator directory.

*Type of Facility (if your facility offers home infusion services, also check "Home Infusion"):

- Ambulatory Infusion Suite Freestanding Center/Clinic Hospital Outpatient Department (HOPD) Home Infusion Prescribing MD's Office

If you are a home infusion service, please call Searchlight Support® for enrollment assistance.

If you are a facility with more than 10 infusion locations, please call Searchlight Support® for enrollment assistance.

Private The information in this section is for validation purposes only and will not be available in search results.

*Facility National Provider Identifier (NPI) _____ and/or *Facility Health Industry Number (HIN) _____

*Primary Contact Name _____ *Primary Contact Phone _____

*Primary Contact Email _____ Primary Contact Fax _____

Public The information below will be available in search results.

*Facility Name _____

*Display Facility Name As _____

*Facility Phone _____

*Healthcare Provider Name (if applicable) _____ *Healthcare Provider NPI _____

*Facility Address _____

*City _____ *State _____ *ZIP Code _____

Website Address _____

Please provide contact information for the person in your office who is responsible for enrolling your practice in the ALS Care Locator for RADICAVA®. This person will receive an email from Searchlight Support®, acknowledging receipt of this information. A representative of Mitsubishi Tanabe Pharma America, Inc. will contact this person if any additional information is needed, or to verify and validate this information.

*Healthcare Provider On Site Yes No

Hours of Operation M _____ Tu _____ W _____ Th _____ F _____ Sa _____ Su _____

Languages Spoken: English French and French Creole Korean Spanish Tagalog German Chinese
 Vietnamese Arabic Additional Languages _____

Insurance Accepted (list all, separated by commas) _____

Special Referral Requirements _____

(Please include information if you only accept referrals from in-network providers, as this will appear in the directory).

*My facility accepts Medicare Yes No

Amenities: TV Meals Beverages Private Rooms Pillows Wheelchair Assistance Reading Materials
 WiFi Snacks Reclining Chairs Headphones Blankets Other _____

*I am an authorized representative of the Facility and I am submitting this information on behalf of the Facility listed on this form.

*The ALS Care Locator is a directory with a number of functions, including a directory of infusion centers that treat ALS and which have opted-in to participate in the directory. This submission information is updated on a monthly basis.

HCPs and infusion centers listed in the directory are not affiliated with Mitsubishi Tanabe Pharma America, Inc. and do not pay to be on this list. No fees or remuneration of any kind have been or will be exchanged for participation in the ALS Care Locator. Inclusion of an infusion center in the ALS Care Locator does not constitute a referral, recommendation, endorsement, or verification of credentials, qualifications, or abilities of the infusion center listed. Similarly, the absence of an infusion center's name and information should not be construed as a negative comment from Mitsubishi Tanabe Pharma America, Inc. about the infusion center's credentials, qualifications, or abilities.

Mitsubishi Tanabe Pharma America, Inc., as well as its employees or agents, shall not be held liable for any damages or harm resulting from any use or reliance on information contained in the ALS Care Locator; and may modify, amend, remove or cancel the ALS Care Locator at any time without notice.

*Name/Title (please print) _____

*Authorized Signature _____ *Date _____

IMPORTANT SAFETY INFORMATION

Most common adverse reactions (at least 10% and greater than placebo) are contusion, gait disturbance, and headache.

Please see full Indication and Important Safety Information on back of form, and accompanying Prescribing Information for RADICAVA®, also available at radicava.com.

INDICATION

Radicava® (edaravone) is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

IMPORTANT SAFETY INFORMATION

Hypersensitivity Reactions

Radicava® is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in Radicava®. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have been reported. Patients should be monitored carefully for hypersensitivity reactions, and if they occur, discontinue Radicava®, treat per standard of care, and monitor until the condition resolves.

Sulfite Allergic Reactions

Radicava® contains sodium bisulfite, and may cause allergic type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown, but occurs more frequently in asthmatic people.

Most Common Adverse Reactions

Most common adverse reactions (at least 10% and greater than placebo) are contusion, gait disturbance, and headache.

Pregnancy

Based on animal data, Radicava® may cause fetal harm.

Geriatric Use

No overall differences in safety or effectiveness were observed between patients 65 years of age and older and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc. at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying Prescribing Information for RADICAVA®, also available at radicava.com.



Mitsubishi Tanabe Pharma America



RADICAVA, the RADICAVA logo, and the corporate symbol of Mitsubishi Tanabe Pharma America are registered trademarks of Mitsubishi Tanabe Pharma Corporation. Searchlight Support is a registered trademark of Mitsubishi Tanabe Pharma America, Inc.

For US audiences only.

Mitsubishi Tanabe Pharma America, Inc.

525 Washington Boulevard, Suite 400

Jersey City, NJ 07310

© 2020 Mitsubishi Tanabe Pharma America, Inc. All rights reserved.

CP-RC-US-1294 03/20